Curing cancer has long been a dream for the human race. Countless doctors, hospitals, foundations and institutions are approaching the eradication of cancer from different angles, and a more focused dream has arisen in the medical community: perhaps we can harness a person’s immune system to treat many types of cancers. Today, immune checkpoint inhibitors and other immuno-modulatory therapies are already on the market and many more are in development. These novel immunotherapy approaches have been successful, and recent evidence shows that they may be even more effective against certain cancers when used in strategic combination.

TapImmune is a leading innovator and world-class clinical-stage immuno-oncology company with multiple ongoing clinical trials. The company is developing next-generation T-cell vaccines with an initial focus on treating ovarian and breast cancer.

Stimulating human T-cells as therapeutics is what TapImmune is all about. We have selected potent antigen combinations that target disease-specific molecules and can be recognized by the vast majority of patients’ immune systems. Our off-the-shelf immunotherapies are designed to treat a wide patient population across varied therapeutic areas of cancer.

Most people these days don’t die from the primary tumor—they die from metastatic disease, where the cancer has traveled to other organs or parts of the body that ultimately can’t be treated. Importantly, TapImmune is developing immunotherapy vaccines designed to create a lasting “memory” T-cell response that may be effective against both the primary tumor and metastases.